Key result
Oral anticoagulant therapy for six months provided no benefit over six weeks for preventing recurrent venous thromboembolism in patients without a history of VTE or continuing predisposing cause.
Why the study?
Does oral anticoagulant therapy for six months compared to six weeks reduce recurrent venous thromboembolism in patients after venous thromboembolism?
Population
186 patients after venous thromboembolism
Comparison
Oral anticoagulant therapy for six months vs Oral anticoagulant therapy for six weeks
Design
RCT, randomized
Authors
Loading...
Supports six-week anticoagulation after first VTE without ongoing risks; confirms no benefit from extension to six months.
RCT (n=186)
Does oral anticoagulant therapy for six months compared to six weeks reduce recurrent venous thromboembolism in patients after venous thromboembolism?
Six weeks of oral anticoagulant therapy appears sufficient for patients with a first episode of venous thromboembolism without continuing predisposing causes.
E. F. O'Sullivan (1972) conducted an RCT in Venous thromboembolism (n=186). Oral anticoagulant therapy for six months vs. Oral anticoagulant therapy for six weeks was evaluated on Recurrent venous thromboembolism. Oral anticoagulant therapy for six months provided no benefit over six weeks for preventing recurrent venous thromboembolism in patients without a history of VTE or continuing predisposing cause.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: